在慢性淋巴细胞白血病中对亡的治疗向
Inhye E Ahn1, Matthew S Davids1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Seminars in hematology
|March 27, 2024
概括
维尼托克拉克斯对慢性淋巴细胞白血病 (CLL) 有效,但可以产生耐药性. 当患者停止治疗时,用venetoclax重新治疗常常对复发的CLL成功,而持续暴露可能需要替代治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 维内托克拉克斯是一种B细胞淋巴瘤2 (BCL-2) 抑制剂,在慢性淋巴细胞白血病 (CLL) 中显示出高疗效,诱导深度和持续的反应.
- 虽然对以前没有接受过治疗的患者有益,但在时间有限的venetoclax组合后,在复发性/耐药性CLL中,具有不利的遗传学 (例如TP53异常,不变异的IGHV) 后,持久缓解时间较短.
研究的目的:
- 调查疾病进展背景对CLL中venetoclax再治疗疗效的影响.
- 探索venetoclax耐药性的机制,并确定替代治疗策略.
主要方法:
- 对不同疾病进展模式的CLL患者的venetoclax治疗结果新出现的数据的分析.
- 审查基因和功能机制背后的venetoclax耐药性,包括BCL2突变和改变的BCL-2家族蛋白相互作用.
- 对针对亡途径的新型治疗策略的评估.
主要成果:
- 持续暴露于venetoclax可以通过BCL2突变或功能性抵抗 (例如,BCL-2高酸化,MCL-1依赖) 来选择耐药的CLL克隆.
- 持续使用venetoclax进展的患者可能会从转换到替代向药物中受益.
- 经过有限时间的venetoclax疗法后的非治疗期后复发的CLL通常仍然对venetoclax重新治疗敏感.
结论:
- 疾病进展的模式影响了在CLL中重新治疗venetoclax的成功.
- 了解耐药机制对于优化CLL治疗和指导治疗决策至关重要.
- 下一代BCL-2抑制剂和向MCL-1代表了对CLL有前途的未来治疗途径.
关键词:
乙细胞淋巴瘤 2 B细胞淋巴瘤慢性淋巴细胞白血病 慢性淋巴细胞白血病灭症 (apoptosis) 是一种死亡的过程.最少残留疾病的最小残留疾病.维尼托克莱克斯 (Venetoclax) 是一个更多相关视频
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
11.4K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.1K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Cytotoxic T Cells-mediated Immune Response
907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907
01:17The Extrinsic Apoptotic Pathway
6.4K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K